SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Abgenix, Inc. (ABGX)
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Miljenko Zuanic who wrote (513)11/3/2005 8:56:15 PM
From: John McCarthy  Read Replies (1) of 590
 
MJ

Gonna stick both feet in my mouth .....

Your point INFERS that both drugs had the
SAME batch of people ....

that is - the batch of people had 1 freckle or
5 freckles or whatever ...... and that batch of
people was used by both drugs .....

and on that basis you want to see the X's and Y's
for comparison .....


the press releases (today) indicated (I can't talk to their
accuracy) that E and P used DIFFERENT batches of
people .... and that P used a harder batch .....
(BUT I CANNOT QUANTIFY IT)


finally to complete my stupidity .....

this is from the trial definition - but let me QUICKLY
add I am not certain that this is the CORRECT trial
in that P has 10 trials going on ... but this is
the only P3 that I could find .....

SEVERE EDIT

Study Type: Interventional
Study Design: Treatment, Randomized, Open Label, Active Control, Parallel Assignment

Official Title: PACCE: A Randomized, Open-Label, Controlled, Clinical Trial of Chemotherapy and Bevacizumab with and Without Panitumumab in the First-Line Treatment of Subjects with Metastatic Colorectal Cancer

Further Study Details:

Primary Outcomes:

Whether treatment with panitumumab given concomitantly with every 2 (Q2) week oxaliplatin-based chemotherapy and bevacizumab improves progression-free survival (PFS) compared to treatment with Q2-week oxaliplatin-based chemotherapy and bevacizumab alone


Secondary Outcomes:

Whether treatment with panitumumab given concomitantly with oxaliplatin-based chemotherapy and bevacizumab improves the following; endpoints compared to treatment with oxaliplatin-based chemotherapy and bevacizumab alone:; -Overall survival (OS) -Response rates (complete [CR] and

clinicaltrials.gov

finally apologies in advance if I just ain't seeing
whats being discussed here ....

regards,
John McCarthy
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News